International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1

International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1 - International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1 (CONVO-GC-1)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022321

Enrollment

900

Registered

2016-05-16

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

StageIV gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To clarify the meaning of conversion therapy, we need to collect all stage IV gastric cancer patients who underwent operation with successful chemoradiationtherapy. 1. Histologically proven primary gastric adenocarcinoma. 2. Stage IV gastric cancer patients initially regarded as non-curably resectable but with successful chemotherapy, regarded as curably resectable (R0), then underwent radical operation (including metastasectomy). 3. Stage IV gastric cancer patients initially regarded as resectable, underwent radical operation after chemotherapy (neoadjuvant case). 4. Stage IV gastric cancer patients with peritoneal dissemination or positive cytology by staging laparoscopy or laparotomy but with successful chemotherapy, then underwent radical operation, or patients who underwent gastrectomy irrespective of chemotherapy.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The rate of operative complications after conversion therapy	—

Secondary

Measure	Time frame
Overall Survival(OS), Relapse free survival(RFS), Response rate, and Histological response	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactMami SAKURAI

Federation of Asian Clinical Oncology (FACO) Tokyo Office

faco-office@jsco.or.jp03-5542-0546

Outcome results